ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Identification and reversal of treatment resistance mechanisms of clinically refractory tumor cells is critical for successful cancer therapy. Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)–based chemoradiation therapy and provide evidence for a functional role of ABCB5 in colorectal cancer 5-FU resistance. Examination of human colon and colorectal cancer specimens revealed ABCB5 to be expressed only on rare cells within healthy intestinal tissue, whereas clinical colorectal cancers exhibited substantially increased levels of ABCB5 expression. Analysis of successive, patient-matched biopsy specimens obtained prior to and following neoadjuvant 5-FU–based chemoradiation therapy in a series of colorectal cancer patients revealed markedly enhanced abundance of ABCB5-positive tumor cells when residual disease was detected. Consistent with this finding, the ABCB5-expressing tumor cell population was also treatment refractory and exhibited resistance to 5-FU–induced apoptosis in a colorectal cancer xenograft model of 5-FU monotherapy. Mechanistically, short hairpin RNA–mediated ABCB5 knockdown significantly inhibited tumorigenic xenograft growth and sensitized colorectal cancer cells to 5-FU–induced cell killing. Our results identify ABCB5 as a novel molecular marker of therapy-refractory tumor cells in colorectal cancer patients and point to a need for consistent eradication of ABCB5-positive resistant tumor cell populations for more effective colorectal cancer therapy. Cancer Res; 71(15); 5307–16. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Adaptation of core mechanisms to generate cell polarity
Nelson, W. J. (2003) · Nature · doi:10.1038/nature01602 · Cited by 716 · cited 1×
“Interestingly, ABCB5 and CD133 were expressed on opposite poles of individual cells, in keeping with the phenomenon of apico-basal polarity attributed to normal columnar epithelial cells (35).”
BackgroundMoitra, K., Lou, H., & Dean, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.14 · Cited by 279
Cammareri, P., Scopelliti, A., Todaro, M., Eterno, V., Francescangeli, F., Moyer, M. P., Agrusa, A., Dieli, F., Zeuner, A., & Stassi, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3953 · Cited by 159 · cited 1×
“For example, in vitro treatment of human HT-29 colorectal cancer cells with high doses of 5-FU resulted in significant enrichment of CD133 colorectal cancer subpopulations (11) and CD133 colorectal cancer cells can be sensitized to 5-FU- or oxaliplatin-mediated cell killing using an anti-IL-4 neutralizing antibody (12…”
Background
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Cancer stem cells: The challenges ahead
Medema, J. P. (2013) · Nature Cell Biology · doi:10.1038/ncb2717 · Cited by 741
Understanding cancer stem cell heterogeneity and plasticity
Tang, D. G. (2012) · Cell Research · doi:10.1038/cr.2012.13 · Cited by 563
The developing cancer stem-cell model: clinical challenges and opportunities
Vermeulen, L., de Sousa e Melo, F., Richel, D. J., & Medema, J. P. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70257-1 · Cited by 393
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Metadata
- Authors
- Wilson, B. J., Schatton, T., Zhan, Q., Gasser, M., Ma, J., Saab, K. R., Schanche, R., Waaga-Gasser, A.-M., Gold, J. S., Huang, Q., Murphy, G. F., Frank, M. H., & Frank, N. Y.
- Venue
- Cancer Research
- Published
- 2011-07-28
- Volume
- 71
- Issue
- 15
- Pages
- 5307-5316
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2049731799
- Cited by
- 136
- References
- 4
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0221
- The paper
- Wilson, B. J., Schatton, T., Zhan, Q., Gasser, M., Ma, J., Saab, K. R., Schanche, R., Waaga-Gasser, A.-M., Gold, J. S., Huang, Q., Murphy, G. F., Frank, M. H., & Frank, N. Y. (2011). ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.